FDA Approved: PARSABIV — Supplemental Application (Amgen, Inc)

View source ↗

Summary

FDA approved a supplemental application for PARSABIV (etelcalcetide) from Amgen, Inc., updating the labeling as part of the supplemental submission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease Requiring Dialysis
• End-stage Renal Disease
• Hyperparathyroidism

Drugs mentioned

• Parsabiv (etelcalcetide)

Snippet

SUPPL AP for PARSABIV (ETELCALCETIDE)